PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

  04 November 2020

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a deployment in Texas of its investigational PhageBank™ therapy in response to a deadly outbreak of secondary infections with carbapenem resistant Acinetobacter baumannii (CRAB) bacteria in COVID-19 patients. Mortality rates were more than two-fold higher in COVID-19 patients with secondary CRAB infection, versus 32% mortality in patients without secondary CRAB infections.

Further reading: BusinessWire
Author(s): BusinessWire
Healthy Patients  
Back


International Matchmaking Symposium 18 November 2020

Emerging Antimicrobials & Diagnostics in AMR 2020

 

4th AMR Insights International Symposium to provide an international online podium for emerging preventives, new antimicrobial strategies, microbial diagnostics and related (platform) technologies.

 

Read more and register >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!